| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30068105 | HIV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS30068106 | HIV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20062080 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20061501 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20023329 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20038182 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20061739 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
| TVIS20043130 | HPV | ENSG00000181072.12 | protein_coding | CHRM2 | No | No | 1129 | A4D1Q0 P08172 Q6SL56 Q6SL59 Q86SJ1 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CHRM2 |
|---|---|
| DrugBank ID | DB00572 |
| Drug Name | Atropine |
| Target ID | BE0000560 |
| UniProt ID | P08172 |
| Regulation Type | antagonist |
| PubMed IDs | 16248990; 17087737; 15333678; 17588565; 16188951; 7855217; 22222705; 1323653 |
| Citations | Roman S, Badia A, Camps P, Munoz-Torrero D, Clos MV: Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors. Brain Res. 2005 Nov 9;1061(2):73-9. Epub 2005 Oct 24.@@Minaba M, Ichiyama S, Kojima K, Ozaki M, Kato Y: Activation of nematode G protein GOA-1 by the human muscarinic acetylcholine receptor M2 subtype. Functional coupling of G-protein-coupled receptor and G protein originated from evolutionarily distant animals. FEBS J. 2006 Dec;273(24):5508-16. Epub 2006 Nov 3.@@May LT, Lin Y, Sexton PM, Christopoulos A: Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. J Pharmacol Exp Ther. 2005 Jan;312(1):382-90. Epub 2004 Aug 27.@@Cembala TM, Forde SC, Appadu BL, Lambert DG: Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors. Eur J Pharmacol. 2007 Aug 13;569(1-2):37-40. Epub 2007 May 22.@@Nelson CP, Nahorski SR, Challiss RA: Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2006 Jan;316(1):279-88. Epub 2005 Sep 27.@@Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.@@Buels KS, Fryer AD: Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;(208):317-41. doi: 10.1007/978-3-642-23274-9_14.@@Wall SJ, Yasuda RP, Li M, Ciesla W, Wolfe BB: Differential regulation of subtypes m1-m5 of muscarinic receptors in forebrain by chronic atropine administration. J Pharmacol Exp Ther. 1992 Aug;262(2):584-8. |
| Groups | Approved; Vet_approved |
| Direct Classification | Tropane alkaloids |
| SMILES | CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1 |
| Pathways | |
| PharmGKB | PA448505 |
| ChEMBL | CHEMBL517712 |
